27.07.2020 12:58:00
|
Emergent Agrees With AstraZeneca To Deploy CDMO Services For COVID-19 Vaccine Candidate
(RTTNews) - Emergent BioSolutions Inc. (EBS) has agreed to provide contract development and manufacturing services for large-scale commercial drug substance manufacturing for AstraZeneca's COVID-19 vaccine candidate, AZD1222. The deal is valued at approximately $174 million through 2021. The agreement is in addition to the public-private CDMO partnership between Emergent and the Biomedical Advanced Research and Development Authority (BARDA) announced in June.
The vaccine candidate, AZD1222, was co-invented by the University of Oxford and its spin-out company, Vaccitech, and licensed by AstraZeneca. The vaccine candidate is currently in clinical trials.
Emergent BioSolutions will provide an update to its 2020 financial outlook incorporating expectations related to the agreement.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Emergent BioSolutions Inc.mehr Nachrichten
05.11.24 |
Ausblick: Emergent BioSolutions stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net) |
Analysen zu Emergent BioSolutions Inc.mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 72,50 | 2,84% |
|
Emergent BioSolutions Inc. | 6,83 | -19,50% |
|